Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

$10 Million Bet On Dyne Therapeutics? Check Out These 4 Stocks Insiders Are Buying

Published 15/12/2022, 14:15
© Reuters.  $10 Million Bet On Dyne Therapeutics? Check Out These 4 Stocks Insiders Are Buying

Benzinga - Although US stocks closed lower on Wednesday following Fed’s rate decision, there were a few notable insider trades.

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

NanoString Technologies

  • The Trade: NanoString Technologies, Inc. (NASDAQ: NSTG) President and CEO Bradley Gray acquired a total of 67,661 shares an average price of $7.38. To acquire these shares, it cost around $499.37 thousand.
  • What’s Happening: NanoString and Abcam, last month, expanded collaboration to advance spatial multiomics research.
  • What NanoString Technologies Does: NanoString Technologies Inc is engaged in the development, manufacturing and commercialization of instruments, consumables, and services for efficiently profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample.

Dyne Therapeutics

  • The Trade: Dyne Therapeutics, Inc. (NASDAQ: DYN) Director Jason Rhodes acquired a total of 934,581 shares at an average price of $10.70. To acquire these shares, it cost around $10 million.
  • What’s Happening: JP Morgan recently maintained Dyne Therapeutics with an Overweight and lowered the price target from $24 to $18.
  • What Dyne Therapeutics Does: Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Also check this: Investor Optimism Declines Slightly Following Fed's Rate Hike

Global Payments

  • The Trade: Global Payments Inc. (NYSE: GPN) Director Robert Baldwin Jr bought a total of 3,400 shares at an average price of $98.62. To acquire these shares, it cost around $335.31 thousand.
  • What’s Happening: Mizuho recently maintained Global Payments with a Neutral and lowered the price target from $132 to $115.
  • What Global Payments Does: Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants.

Harrow Health

  • The Trade: Harrow Health, Inc. (NASDAQ: HROW) 10% owner Opaleye Management Inc bought a total 431,183 shares at an average price of $10.52. The insider spent around $4.54 million to buy those shares.
  • What’s Happening: Harrow Health entered an agreement to acquire exclusive U.S. commercial rights to five FDA approved ophthalmic products from Novartis group for $130 million.
  • What Harrow Health Does: Harrow Health Inc is an ophthalmology-focused pharmaceutical company.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.